Abstract
We evaluated the activity of CB-183,315 against Clostridium difficile, including strains that are resistant to fluoroquinolones and metronidazole and with elevated MICs to vancomycin as well as other Gram-positive intestinal pathogens. The MICs of CB-183,315 against all C. difficile isolates were ≤ 1 μg/ml. CB-183,315 had greater activity than vancomycin and metronidazole against C. difficile isolates and was more active than the comparators against vancomycin-resistant enterococcus (VRE). CB-183,315 also had excellent activity against methicillin-resistant Staphylococcus aureus (MRSA), other Clostridium spp., and Peptostreptococcus spp.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-Bacterial Agents / pharmacology*
-
Clostridioides difficile / drug effects*
-
Clostridioides difficile / pathogenicity
-
Drug Resistance, Multiple, Bacterial
-
Enterococcus / drug effects
-
Enterococcus / pathogenicity
-
Intestines / microbiology*
-
Lipopeptides / pharmacology*
-
Methicillin-Resistant Staphylococcus aureus / drug effects
-
Methicillin-Resistant Staphylococcus aureus / pathogenicity
-
Metronidazole / pharmacology
-
Microbial Sensitivity Tests
-
Peptostreptococcus / drug effects
-
Peptostreptococcus / pathogenicity
-
Vancomycin / pharmacology*
Substances
-
Anti-Bacterial Agents
-
Lipopeptides
-
Metronidazole
-
Vancomycin